Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leonard Reyno

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Investigational New Drugs|February 7, 2019
A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancerDeaglan McHugh, Mario Eisenberger, Elisabeth I Heath, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2004
Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19Leonard Reyno, Lesley Seymour, Dongsheng Tu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 2018
Phase I Trials of Anti-ENPP3 Antibody-Drug Conjugates in Advanced Refractory Renal Cell CarcinomasJohn A Thompson, Robert J Motzer, Ana M Molina, et al.
Cell Reports|October 23, 2021
Targeting TREM2 on tumor-associated macrophages enhances immunotherapyMikhail Binnewies, Joshua L Pollack, Joshua Rudolph, et al.
Journal of Medicinal Chemistry|November 24, 2025
Discovery of CFT8634, a Potent, Selective, and Orally Bioavailable Heterobifunctional Degrader of BRD9Katrina L Jackson, Ning Yin, Roman V Agafonov, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Investigational New Drugs|February 7, 2019
A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancerDeaglan McHugh, Mario Eisenberger, Elisabeth I Heath, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2004
Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19Leonard Reyno, Lesley Seymour, Dongsheng Tu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 2018
Phase I Trials of Anti-ENPP3 Antibody-Drug Conjugates in Advanced Refractory Renal Cell CarcinomasJohn A Thompson, Robert J Motzer, Ana M Molina, et al.
Cell Reports|October 23, 2021
Targeting TREM2 on tumor-associated macrophages enhances immunotherapyMikhail Binnewies, Joshua L Pollack, Joshua Rudolph, et al.
Journal of Medicinal Chemistry|November 24, 2025
Discovery of CFT8634, a Potent, Selective, and Orally Bioavailable Heterobifunctional Degrader of BRD9Katrina L Jackson, Ning Yin, Roman V Agafonov, et al.
Pageof 2